Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model

• Published in: Oncotarget Vol. 6; no. 31; pp. 31233 - 31240
• Main Authors: Lamming, Dudley W, Cummings, Nicole E, Rastelli, Antonella L, Gao, Feng, Cava, Edda, Bertozzi, Beatrice, Spelta, Francesco, Pili, Roberto, Fontana, Luigi
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 13.10.2015
• Subjects: Animals; Blotting, Western; Breast Neoplasms - diet therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Dietary Proteins - administration & dosage; Dietary Proteins - pharmacology; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred NOD; Mice, SCID; Multiprotein Complexes - antagonists & inhibitors; Multiprotein Complexes - metabolism; Phosphorylation; Research Paper; Signal Transduction; TOR Serine-Threonine Kinases - antagonists & inhibitors; TOR Serine-Threonine Kinases - metabolism; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; protein restriction; mTOR; cancer; aging; mice
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.5180

Reduced dietary protein intake and intermittent fasting (IF) are both linked to healthy longevity in rodents, and are effective in inhibiting cancer growth. The molecular mechanisms underlying the beneficial effects of chronic protein restriction (PR) and IF are unclear, but may be mediated in part by a down-regulation of the IGF/mTOR pathway. In this study we compared the effects of PR and IF on tumor growth in a xenograft mouse model of breast cancer. We also investigated the effects of PR and IF on the mechanistic Target Of Rapamycin (mTOR) pathway, inhibition of which extends lifespan in model organisms including mice. The mTOR protein kinase is found in two distinct complexes, of which mTOR complex 1 (mTORC1) is responsive to acute treatment with amino acids in cell culture and in vivo. We found that both PR and IF inhibit tumor growth and mTORC1 phosphorylation in tumor xenografts. In somatic tissues, we found that PR, but not IF, selectively inhibits the activity of the amino acid sensitive mTORC1, while the activity of the second mTOR complex, mTORC2, was relatively unaffected by PR. In contrast, IF resulted in increased S6 phosphorylation in multiple metabolic tissues. Our work represents the first finding that PR may reduce mTORC1 activity in tumors and multiple somatic tissues, and suggest that PR may represent a highly translatable option for the treatment not only of cancer, but also other age-related diseases.